首页> 外文期刊>Protein engineering design & selection: PEDS >Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo
【24h】

Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo

机译:基于白喉毒素的重组鼠IL-2融合毒素,可在体内消耗鼠调节性T细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Regulatory T cells (Tregs) are a subpopulation of CD4+ T cells which suppress immune responses of effector cells and are known to play a very important role in protection against autoimmune disease development, induction of transplantation tolerance and suppression of effective immune response against tumor cells. An effective in vivo Treg depletion agent would facilitate Treg-associated studies across many research areas. In this study, we have developed diphtheria toxin-based monovalent and bivalent murine IL-2 fusion toxins for depleting murine IL-2 receptor positive cells including CD251 Treg in vivo. Their potencies were assessed by in vitro protein synthesis inhibition and cell proliferation inhibition assays using a murine CD25+ CTLL-2 cell line. Surprisingly, in contrast to our previously developed recombinant fusion toxins, the monovalent isoform (DT390-mIL-2) was approximately 4-fold more potent than its bivalent counterpart (DT390- bi-mIL-2). Binding analysis by flow cytometry demonstrated that the monovalent isoform bound stronger than the bivalent version. In vivo Treg depletion with the monovalent murine IL-2 fusion toxin was performed using C57BL/ 6J (B6) mice. Spleen Treg were significantly depleted with a maximum reduction of ~70% and detectable as early as 12 h after the last injection. The spleen Treg numbers were reduced until Day 3 and returned to control levels by Day 7. We believe that this monovalent murine IL-2 fusion toxin will be an effective in vivo murine Treg depleter.
机译:调节性T细胞(Tregs)是CD4 + T细胞的一个亚群,可抑制效应细胞的免疫反应,并且在保护自身免疫疾病发展,诱导移植耐受性以及抑制针对肿瘤细胞的有效免疫反应中起着非常重要的作用。有效的体内Treg耗竭剂将促进跨许多研究领域的Treg相关研究。在这项研究中,我们已经开发出基于白喉毒素的单价和二价鼠类IL-2融合毒素,用于体内耗尽包括CD251 Treg在内的鼠类IL-2受体阳性细胞。通过使用鼠CD25 + CTLL-2细胞系进行体外蛋白质合成抑制和细胞增殖抑制测定,评估了它们的效力。出乎意料的是,与我们先前开发的重组融合毒素相反,单价同工型(DT390-mIL-2)的效价比其二价同工型(DT390-bi-mIL-2)高约4倍。通过流式细胞术的结合分析表明,单价同工型结合比二价同种型更强。使用C57BL / 6J(B6)小鼠进行单价鼠IL-2融合毒素的体内Treg去除。脾脏Treg明显减少,最大减少量约为70%,最早可在最后一次注射后12 h检出。脾脏Treg数量减少至第3天,并在第7天恢复到对照水平。我们相信这种单价鼠IL-2融合毒素将是体内有效的鼠Treg消耗者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号